INDP vs. MIST, PYRGF, CUE, HOOK, DERM, MRNS, IOBT, YS, ANIX, and SPRO
Should you be buying Indaptus Therapeutics stock or one of its competitors? The main competitors of Indaptus Therapeutics include Milestone Pharmaceuticals (MIST), PyroGenesis Canada (PYRGF), Cue Biopharma (CUE), Hookipa Pharma (HOOK), Journey Medical (DERM), Marinus Pharmaceuticals (MRNS), IO Biotech (IOBT), YS Biopharma (YS), Anixa Biosciences (ANIX), and Spero Therapeutics (SPRO). These companies are all part of the "pharmaceutical preparations" industry.
Indaptus Therapeutics (NASDAQ:INDP) and Milestone Pharmaceuticals (NASDAQ:MIST) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, earnings, community ranking, media sentiment, institutional ownership, profitability and dividends.
Milestone Pharmaceuticals received 67 more outperform votes than Indaptus Therapeutics when rated by MarketBeat users. However, 83.33% of users gave Indaptus Therapeutics an outperform vote while only 68.14% of users gave Milestone Pharmaceuticals an outperform vote.
Indaptus Therapeutics currently has a consensus target price of $12.00, indicating a potential upside of 406.33%. Milestone Pharmaceuticals has a consensus target price of $10.75, indicating a potential upside of 616.67%. Given Milestone Pharmaceuticals' higher possible upside, analysts clearly believe Milestone Pharmaceuticals is more favorable than Indaptus Therapeutics.
Indaptus Therapeutics has a beta of 1.28, indicating that its share price is 28% more volatile than the S&P 500. Comparatively, Milestone Pharmaceuticals has a beta of 1.77, indicating that its share price is 77% more volatile than the S&P 500.
7.1% of Indaptus Therapeutics shares are owned by institutional investors. Comparatively, 86.2% of Milestone Pharmaceuticals shares are owned by institutional investors. 29.5% of Indaptus Therapeutics shares are owned by insiders. Comparatively, 10.4% of Milestone Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Indaptus Therapeutics has higher earnings, but lower revenue than Milestone Pharmaceuticals. Indaptus Therapeutics is trading at a lower price-to-earnings ratio than Milestone Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Indaptus Therapeutics' return on equity of -108.14% beat Milestone Pharmaceuticals' return on equity.
In the previous week, Milestone Pharmaceuticals had 3 more articles in the media than Indaptus Therapeutics. MarketBeat recorded 7 mentions for Milestone Pharmaceuticals and 4 mentions for Indaptus Therapeutics. Indaptus Therapeutics' average media sentiment score of 1.03 beat Milestone Pharmaceuticals' score of 0.48 indicating that Indaptus Therapeutics is being referred to more favorably in the media.
Summary
Milestone Pharmaceuticals beats Indaptus Therapeutics on 10 of the 16 factors compared between the two stocks.
Get Indaptus Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for INDP and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding INDP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Indaptus Therapeutics Competitors List
Related Companies and Tools
